Earlier this month, Aegerion Pharmaceuticals (NASDAQ:AEGR) missed analyst expectations for Juxtapid, with sales coming in at $27 million, and the company lowered guidance for the year to a range of $180 million to $200 million, from a ranger of $190 million to $210 million.
In the following video, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the situation with Aegerion Pharmaceuticals and the orphan-drug model in general.
For Juxtapid, it's hard to know if competition is an issue, because its closest competitor, Kynamro, is sold by Sanofi (NYSE:SNY) which doesn't break out sales since they're not material to the larger company. Kynamro was developed by Isis Pharmaceuticals (NASDAQ:IONS), which is materially affected by sales, but the biotech isn't able to give investors information on the launch because it's fully under Sanofi's control.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Apple and Isis Pharmaceuticals and owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Aegerion Pharmaceuticals' Stock Bolted Higher Today
An analyst upgrade sent share of the drugmaker higher today.
Aegerion Pharmaceuticals Lost a Third of Its Value in November: Time to Buy?
Competitive threats to Aegerion's flagship medicine sent shares spiraling downward in November.
Why Aegerion Pharmaceuticals Is Crashing Today
New drug launches are beginning to dent demand for the company's top selling medication.